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Abstract: A novel approach for the synthesis of unsymmetrically substituted 
dibenzo[b,f][1,5]diazocine-6,12(5H,11H)diones has been developed. This facile three-step method 
uses variously substituted 1H-benzo[d][1,3]oxazine-2,4-diones (isatoic anhydrides) and 
2-aminobenzoic acids as a starting materials. The obtained products were further transformed into 
N-alkyl-, N-acetyl- and dithio analogues. Developed procedures allowed the synthesis of 
unsymmetrical dibenzo[b,f][1,5]diazocine-6,12(5H,11H)diones and three novel heterocyclic 
scaffolds: benzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)dione, 
pyrido[3,2-c][1,5]benzodiazocine-5,11(6H,12H)-dione and 
pyrazino[3,2-c][1,5]benzodiazocine-6,12(5H,11H)dione. For 11 of the compounds crystal structures 
were obtained. The preliminary cytotoxic effect against two cancer (HeLa, U87) and two normal 
lines (HEK293, EUFA30) as well as antibacterial activity were determined. The obtained 
dibenzo[b,f][1,5]diazocine(5H,11H)6,12-dione framework could serve as a privileged structure for 
the drug design and development. 
Keywords: unsymmetrical dibenzo[b,f][1,5]diazocines; isatoic anhydrides; crystallographic 
analysis; cytotoxicity; heterocycles 
 
1. Introduction 
Tricyclic dibenzodiazepines and their structural analogues (dibenzoazepines, 
dibenzothiazepines and others) having two non-polar, aromatic benzene or heterocyclic rings 
separated by a seven-membered ring containing heteroatoms such as sulfur, nitrogen or oxygen (1, 
Figure 1), are very popular, privileged structures, useful for the development of drugs, as well as 
compounds with various biological activities and applications (Figure 1). Modulation of biological 
properties is possible by skillful chemical modifications, and variation of substituents and 
functional groups located in the six-membered benzene rings and the seven-membered heterocyclic 
ring. This group of compounds includes such important drugs as imipramine (2; a dibenzoazepine 
with antidepressant activity and a serotonin and norepinephrine reuptake inhibitor) [1], 
clobenzepam (3; dibenzodiazepine; antihistaminic and anticholinergic) [2], quetiapine (4; 
dibenzothiazepine; antipsychotic activity; dopamine, serotonin, and adrenergic receptors 
antagonist) [3], oxcarbazepine (5; dibenzoazepine; anticonvulsant activity; voltage-sensitive sodium 
channels blocker) [4,5], and nevirapine (6; dipyridodiazepine; anti-HIV; non-nucleoside reverse 
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transcriptase inhibitor) [6]. Additionally, we recently reported [7] the synthesis of structurally 
related, tricyclic pyrazinebenzodiazepines type 7. Surprisingly, these compounds exhibited a 
promising cytotoxic effect against two cancer cell lines: LoVo (human colon cancer) and MV-4-11 
(biphenotypic B myelomonocytic leukemia) [8]. 
Figure 1. Tricyclic 7-th membered dibenzoheterocycles and their analogues. 
Tricyclic dibenzoheterocycles 2–5, and their tricyclic analogues possessing pyridine 6 or 
piperidine 7 rings are widely used in the design and search for new compounds of biological 
importance. On the other hand, analogous tricyclic systems containing two non-polar, aromatic 
benzene rings separated by a larger, eight-membered heterocyclic ring—tricyclic dibenzodiazocines 
and their structural analogs (8, Figure 2) are not practically used in the design of biologically active 
compounds despite their high potential. This situation is caused by the lack of appropriate synthetic 
routes leading to this type of compounds. A rare example of the application of such heterocyclic 
scaffolds in the design of compounds exhibiting biological activity involves the use of compound 9 
(Figure 2) as a chemosensitizer, abolishing the activity of a glycoprotein (GP 170) located in the cell 
membrane, and increasing the penetration of the drug into the cell [9,10]. 
 
Figure 2. Tricyclic, 8-membered dibenzoheterocycles. 
In our continuous research on the development of medicinally relevant compounds possessing 
the dilactam structure [7,8], we recently focused on the dibenzo[b,f][1,5]diazocine scaffold 10 as a 
possible framework for the design of biologically active substances. Our literature survey revealed 
that symmetrical compounds type 10 (R1 = R2, R3 = R4) could be obtained in the dimerization 
reaction of substituted 2-aminobenzoic acids (anthranilic acids) in the presence of phosphorus 
oxychloride [9] or in the dimerization reaction of alkyl 2-aminobenzoates after treatment with 
sodium hydride [11]. These methods, based on the dimerization of two moieties of 2-aminobenzoic 
acids or their esters, allow for high-yield syntheses of symmetrical dibenzo[b,f][1,5]diazocines but 
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are completely unsuitable for synthesis of more complex and unsymmetrical compounds type 10, 
possessing various substituents in the aromatic and dilactam rings (R1 ≠ R2, R3  ≠ R4). It is obvious 
that by limiting the ability to modify the structure of a compound, one reduces its potential use in 
the design of biologically active agents. This limits the modulation of biological activity, as well as 
physicochemical properties, where the key to success is the skilful introduction and modification of 
substituents and side chains attached to the heterocyclic scaffold. Compounds possessing the 
dibenzo[b,f][1,5]diazocine structure 10, could be also treated as small cyclic dipeptides, consisting of 
two aromatic β-amino acid units. Consequently, synthetic efforts have been directed toward 
cyclisation of 2-(2-aminobenzamido)benzoic acids 11 (Scheme 1) in the presence of classical peptide 
coupling reagents [11,12]. Unfortunately, as reported [12], and confirmed in our laboratory, this 
approach led exclusively to the formation of yellow-coloured, bicyclic products possessing the 
2-(2-aminophenyl)-4H-benzo[d][1,3]oxazin-4-one structure 12. We also observed, and proved by the 
single-crystal X-ray diffraction analysis, that crystallization of compound 12 (R1 = R2 = H) from 
water-methanol mixture, in the presence of p-toluenesulphonic acid (1 equivalent), led to its 
hydrolysis to 2-(2-aminobenzamido)benzoic acid 11 (R1 = R2 = H), crystallized as a 
4-toluenesulphonate salt 11*TsOH (for the crystallographic details see the Supporting Information 
file). The application of some other cyclisation agents such as polyphosphate ester (PPE) [12] or 
thionyl chloride [13] for cyclisation of primary amides also led to the product 12, while treatment of 
the N-methyl amide with PPE resulted in the formation of the dibenzo[b,f][1,5]diazocine scaffold 
[12]. These results suggest that the use of cyclisation agents such as carbodiimides, PPE or thionyl 
chloride requires substitution or protection of amide group is necessary to avoid formation of 12. 
 
 
 
 
Scheme 1. DCC-mediated cyclisation of 2-(2-aminobenzamido)benzoic acid 11: Reagents and 
Conditions: a) DCC, DMF, rt, 18 h. 
The only attempt toward the synthesis of unsymmetrical compounds type 10 (R1 ≠ R2, R3 ≠ R4) 
was reported in 2004 [13], where unprotected 2-aminobenzoic acids were initially treated with 
thionyl chloride, and the obtained intermediates were coupled with a second molecule of 
unprotected, differentially C-substituted 2-aminobenzoic acids. That short letter was only limited to 
the general procedure of synthesis and physicochemical data for just one representative product 
containing the dibenzo[b,f][1,5]diazocine structure. In contrast to the high yields of syntheses 
reported in the article, in our hands this method led to the complex mixture of products, including 
benzo[d][1,3]oxazin-4-ones 12 and uncyclized 11. For this reason, we focused on the search for the 
alternative methods for the synthesis of unsymmetrical dibenzo[b,f][1,5]diazocines 10 (R1 ≠ R2, R3 ≠ 
R4). In this paper, we present a high-yielded, three-step procedure based on the synthesis of 
unsymmetrical and variously substituted 2-(2-aminobenzamido)benzoic acids esters, followed by 
basic cyclisation in the presence of sodium hydride. 
2. Results and Discussion 
2.1. Chemistry 
In the present study, we developed two different synthetic approaches to the preparation of 
asymmetrically substituted dibenzo[b,f][1,5]diazocine scaffold 10. The first method is based on the 
application of variously N- and C- and N,C-disubstituted 1H-benzo[d][1,3]oxazine-2,4-diones 
(isatoic anhydrides) 13a–i as coupling partners with variously N- and C-substituted, unprotected 
2-aminobenzoic acids 14a–d (Scheme 2). 
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Scheme 2. First synthetic strategy to the dibenzo[b,f][1,5]diazocine scaffold. Reagents and 
Conditions: a) NaOH, H2O, 80 °C, 30 min; b) H2SO4, MeOH, reflux, 72 h; c) THFanh., 60% NaH, 
reflux, 18 h. 
The previous literature reported one example of the application of 1H-benzo[d]- 
[1,3]oxazine-2,4-diones for the synthesis of the dibenzo[b,f][1,5]diazocine scaffold 10, which was 
limited to symmetrically substituted products [14]. We observed that unsubstituted 
1H-benzo[d][1,3]oxazine-2,4-dione (13c), C-substituted: 6-chloro (13a), 6-bromo- (13b) and 
6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione (13d), N-substituted: 1-methyl- (13e), 1-benzyl- (13g) and 
1-(4-bromobenzyl)-1H-benzo[d][1,3]oxazine-2,4-dione (13h), as well as C,N-disubstituted: 
6-chloro-1-methyl- (13f) and 6-bromo-1-(naphthalen-1-ylmethyl)-1H-benzo[d][1,3]oxazine-2,4-dione 
(13i) could be used as coupling partners with unsubstituted 2-aminobenzoic acid (14a), 
C-substituted: 4,5-dimethoxy-2-aminobenzoic acid (14b) and 3-amino-2-naphthoic acids (14d) and 
N-substituted 2-(methylamino)benzoic acid (14c). The coupling step requires the presence of base, 
one equivalent of sodium hydroxide, and is performed in an aqueous solution at 80 °C [11]. The 
obtained non-symmetrically substituted 2-(2-aminobenzamido)benzoic acids 15a–k were not 
isolated but directly transformed into the appropriate methyl esters 16a–k, by refluxing 15a–k in 
methanol, in the presence of concentrated sulfuric acid [11]. The final cyclisation step of crude 
methyl 2-(2-aminobenzamido)benzoates 16a–k was performed with sodium hydride in refluxing 
anhydrous THF, resulting in dibenzo[b,f][1,5]diazocines 10a–k. In the case of compounds 10a–e, 10h 
and 10j the yield of this three-step synthesis was in the range of 30–35%, giving quite high 
efficiency for a single step synthesis (average yield for one synthesis step). In the case of 
compounds 10f, 10g and 10i, we observed slightly lower efficiency, in the 25–29% range, while 
compound 10k was obtained with 18% yield. 
Table 1. Synthesized compounds. 
Substrate 1 Substrate 2 Product Substrate 1 Substrate 2 Product 
13a 14a 10a 13e 14b 10g 
O
O
N O
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+
HN
R3
OH
O
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R1 N
O R3
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OH
O
R2 R2
b
R1 N
O R3
NH
O
O
R2
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N
N
O
O
R3
R2
R1
13a-i 14a-d 15a-k
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R4
R4R4
R4
O
O
N O
CH3
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13b 14a 10b 13f 14d 
10h 
13b 14b 10c 13g 14a 10i 
13c 14c 10d 13h 14a 10j 
13b 14c 10e 13i 14c 10k 
13d 14c 10f 
   
Unfortunately, the unsubstituted 2-aminonicotinic acid (18a) and 
3-amino-2-pyrazinecarboxylic acid (18b) failed to react with 1H-benzo[d][1,3]oxazine-2,4-diones, 
which forced us to investigate an alternative method for coupling of 18a-b with 2-aminobenzoic 
acids. In the second method, 2-aminonicotinic acid (18a) and 3-amino-2-pyrazinecarboxylic acid 
(18b) were transformed in the first synthesis step into 2-amino-N-sulfinylnicotinoyl chloride (19a) 
and 3-amino-N-sulfinylpyrazine-2-carbonyl chloride (19b) after treatment with SOCl2 in boiling 
toluene (Scheme 3) [13].  
Scheme 3. Second synthetic strategy to obtain the tricyclic diazocine-5,11(6H,12H)-dione scaffold. 
Reagents and Conditions: (a) SOCl2, toluene, reflux, 3 h; (b) toluene, rt, 48 h; (c) THFanh., 60% NaH, 
reflux, 18 h. 
O
O
N
H
O
Br
O
O
N
H
O
Br
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The resulting crude intermediates 19a,b underwent reaction with 2-amino-5-chlorobenzoate 
(20) to form methyl 2-(2-aminonicotinamido)-5-chlorobenzoate (21a) and methyl 
2-(2-aminopyrazine-3-carboxamido)-5-chlorobenzoate (21b). Intermediates 21a,b were not isolated, 
but rather directly treated with sodium hydride in refluxing anhydrous THF, which led to the 
formation of 8-chloropyrido[3,2-c][1,5]benzodiazocine-5,11(6H,12H)-dione (10l), in 17% yield, and 
8-chloropyrazino[3,2-c][1,5]benzodiazocine-6,12(5H,11H)-dione (10m), in 19% yield (total yield for 
the three-step synthesis). 
We also performed post-cyclisation modifications of the reported dibenzo[b,f][1,5]diazocines, 
including alkylation, acylation and thiolation of 8-membered dilactam diazocine-6,12-dione ring 
(Scheme 4). The treatment of 5-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10d) with 
ethyl bromoacetate, in the presence of 60% sodium hydride in mineral oil, led to the formation of 
ethyl 2-(11-methyl-6,12-dioxo-11,12-dihydrodibenzo[b,f][1,5]diazocin-5(6H)-yl)acetate (10n), in 78% 
yield. Heating of 5-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10d) in boiling acetic 
anhydride for 3 h, resulted in the N-acyl derivative, 5-acetyl-11-methyldibenzo[b,f][1,5]diazocine- 
6,12(5H,11H)-dione (10o), in 89% yield. Finally, heating of 8-bromo-2,3-dimethoxy- 
dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10c) with p-tolyl Davy-reagent in boiling anhydrous 
THF for 18 h, led to the formation of the corresponding dithiolactam derivative, 
8-bromo-2,3-dimethoxydibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dithione (10p), in 58% yield. 
Scheme 4. Reagents and Conditions: a) ethyl bromoacetate, 60% NaH, DMSO, rt, 18 h; b) Ac2O, 
reflux, 3 h; c) p-tolyl Davy-reagent, THFanh., reflux, 18 h. 
2.2. Crystallographic Analysis 
Attempts to obtain single-crystals suitable for X-ray diffraction measurements of all 
synthesized dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-diones 10a–o were undertaken. However, they 
were successful in only eight cases (10b, 10g, 10h, 10i, 10j, 10l, 10m and 10o) (Figure 3). The crystal 
structures of three intermediates (11*TsOH, 13i and 14c) were also determined (Figures 1–3 (ESI)). 
Crystals appropriate for diffractometric analysis were grown by slow evaporation from ethanol 
(10h, 10j, 10m), acetone (10b, 10l), ethyl acetate (10g, 13i), hexane:ethyl acetate (14c), 
cyclohexane:ethyl acetate (10o), and water:methanol (11*TsOH) at room temperature. 
The investigated compounds crystallized in the monoclinic P21/c (11*TsOH, 13i, 14c, 10b, 10g, 
10l, and 10m) or C2/c (10i), orthorhombic P212121 (10h) or Pbca (10o) and triclinic P-1 (10j) space 
groups, with one molecule of a compound in the asymmetric unit of the crystal lattice (Figures 4, 1S 
and 2S). The asymmetric unit of 10b contains one molecule of solvent (acetone). The conformation 
of 10a-o resembles a butterfly. The refinement parameters and details of the crystallographic data 
are presented in Table 1S (ESI). The values of valence and torsion angles, together with bond 
lengths are presented in Tables 2S−34S (ESI). 
N
HN
O
O
R2
10c R1=Br, R2=R3=OCH3, R4=H
10d R1=R2=R3=H, R4=CH3
R3R1
from 10c
H
N
HN
S
S
Br
10p
O
O
a)
R4
b)
from 10d
N
N
O
O CH3
O
10n
N
N
O
O CH3
CH3
10o
O
c)
from 10d
O
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Figure 3. Asymmetric unit of the crystal lattice of final products 10b, 10g–j, 10l, 10m, 10o with 
crystallographic atom numbering. Displacement ellipsoids are drawn at the 50% probability level. 
The H-atoms are shown as small spheres of arbitrary radius. 
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2.3. Cytotoxic and Antibacterial Effect of dibenzo[b,f][1,5]diazocine-6,12-diones 10a–p 
We evaluated the cytotoxic efficacy of 16 synthesized dibenzo[b,f][1,5]diazocine-6,12-diones 
10a-p on two normal (HEK293, EUFA30) and two cancerous (HeLa, U87) cell lines (concentrations 
tested: 1–200 µM; Table 2). Among the tested compounds, five showed a cytotoxic effect while 
maintaining the selectivity of action—10b, 10f, 10h, 10j and 10p—their IC50 ranged from several 
dozen (lowest—97.3 µM) to several hundred (higher—205.7 µM). Nevertheless, the IC50 for normal 
cell lines was higher than for cancerous ones. For the majority of the remaining compounds, the IC50 
values were above 1 mM or could not be calculated. 
Table 2. IC50 (µM) of dibenzo[b,f][1,5]diazocine-6,12-diones 10a-p based on the survival of 
non-cancerous (HEK293, EUFA30) and cancerous (U87, HeLa) cells after 24 and 48 h of treatment. 
“*” - Proliferation inhibition at 200 µM, the highest concentration used. 
Compound 
Cell Types 
Eufa30 HEK293 HeLa U87 
24h 48h 24h 48h 24h 48h 24h 48h 
10a [20.7]* ± 
2.4 
[17.7]* ± 
11.2 
[19.2]* ± 
2.5 
[9.7]* ± 
5.2 
[12.2]* ± 
0.1 
[0.7]* ± 
0.1 
[18.9]* ± 
9.1 
[7.2]* ± 
0.6 
10b [27.0]* ± 
15.7 
[21.8]* ± 
2.3 
[18.5]* ± 
7.2 
[18.2]* ± 
4.5 
97.3 ± 
13.7 
[12.7]* ± 
3.6 
[27.0]* ± 
7.7 
[15.9]* ± 
4.5 
10c [41.1]* ± 
8.3 
[0.0]* 
[14.9]* ± 
5.6 
[9.3]* ± 
5.5 
[31.4]* ± 
10.0 
[0.8]* ± 
2.5 
[20.8]* ± 
4.2 
[0.0]* 
10d [17.0]* ± 
27.7 
[16.5]* ± 
3.0 
[12.9]* ± 
8.2 
[0.0]* 
[34.3]* ± 
8.3 
[9.2]* ± 
4.8 
[11.5]* ± 
3.4 
[2.5]* ± 
1.4 
10e [9.8]* ± 
6.2 
[12.2]* ± 
2.7 
[24.3]* ± 
0.4 
[11.2]* ± 
1.7 
[30.7]* ± 
9.0 
[0.9]* ± 
2.4 
[24.4]* ± 
3.1 
[9.4]* ± 
2.4 
10f 
[7.7]* ± 
6.4 
[13.2]* ± 
4.1 
[4.7]* ± 
3.1 
[0.7]* ± 
4.1 
205.7 ± 
12.8 
[5.2]* ± 
1.9 
[30.9]* ± 
0.3 
[3.6]* ± 
2.9 
10g [41.5]* ± 
1.4 
[5.4]* ± 
1.3 
[9.7]* ± 
3.3 
[7.2]* ± 
4.2 
[21.0]* ± 
4.4 
[6.1]* ± 
2.0 
[22.6]* ± 
3.1 
[0.0]* 
10h 170.5 ± 
21.1 
199.8 ± 
13.9 
[37.0]* ± 
18.9 
[33.7]* ± 
10.0 
107.4 ± 
10.0 
107.6 ± 
8.6 
148.6 ± 
9.0 
181.9 ± 
5.6 
10i [20.3]* ± 
1.8 
[20.1]* ± 
5.5 
[24.7]* ± 
5.8 
[25.2]* ± 
2.2 
[31.8]* ± 
5.2 
[5.3]* ± 
2.3 
[27.3]* ± 
6.4 
[5.5]* ± 
0.8 
10j [36.4]* ± 
11.4 
[38.2]* ± 
2.7 
[30.8] ± 
5.4 
192.0 ± 
12.2 
137.5 ± 
14.1 
202.6 ± 
4.0 
[41.8]* ± 
10.8 
[42.4]* ± 
5.7 
10k 87.6 ± 8.1 74.4 ± 6.7 119.0 ± 
7.1 
138.3 ± 
12.0 
75.3 ± 1.6  123.9 ± 
5.4 
75.4 ± 8.7 197.4 ± 
9.4 
10l [12.8]* ± 
3.5 
[9.9]* ± 
2.5 
[12.9]* ± 
2.1 
[5.9]* ± 
2.4 
[23.2]* ± 
10.3 
[0.0]* 
[24.2]* ± 
2.8 
[4.9]* ± 
2.2 
10m [24.0]* ± 
10.1 
[6.3]* ± 
4.8 
[7.9]* ± 
4.0 
[5.6]* ± 
2.0 
[39.1]* ± 
5.2 
[5.0]* ± 
2.3 
[20.5]* ± 
4.2 
[9.9]* ± 
2.9 
10n [8.2] ± 1.2 [0.0]* [0.0]* [0.0]* 
[3.1]* ± 
2.2 
[0.0]* 
[9.9]* ± 
0.8 
[0.0]* 
10o [23.3]* ± 
9.5 
[25.2]* ± 
5.7 
[18.3]* ± 
7.3 
[12.9]* ± 
7.3  
[32.9]* ± 
3.3 
[5.9]* ± 
1.5 
[23.9]* ± 
4.8 
[0.0]* 
10p [33.4]* ± 
2.1 
157.6 ± 
9.6 
202 ± 7.9 144.7 ± 
8.5 
115.2 ± 
4.5 
203.9 ± 
6.5 
172.0 ± 
10.0 
[3.8]* ± 
0.6  
Although the evaluated compounds showed a rather weak cytotoxic effect, we were able to 
establish some relationships between the structure of the compounds and their activity. 
2-Bromodibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10b) showed a very weak cytotoxic effect 
with some selectivity for the HeLa tumor cell line (IC50 = 97.3 µM). Its N-methyl derivative, 
2-bromo-11-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10e), showed a weaker cytotoxic 
effect than the parent compound (IC50 ˃ 200 µM for HeLa). The introduction of an additional 
naphthalen-1-ylmethyl group resulted in the formation of 2-bromo-11-methyl- 
5-(naphthalen-1-ylmethyl)dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10k) showing noticeable 
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cytotoxicity on all cell lines tested (IC50 = 87.6 µM—EUFA, 119.0 µM—HEK293, 75.3 µM—HeLa, 
75.4 µM—U87). We observed that the presence of an additional, large and hydrophobic substituent 
attached to the dilactam ring was beneficial for enhancement of the cytoxic effect. 
2-Chlorodibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10a) and 8-bromo-2,3-dimethoxydibenzo- 
[b,f][1,5]diazocine-6,12(5H,11H)-dione (10c) showed no cytotoxic effect in the concentration range 
tested. Structural modifications of 10a: introduction of another benzene ring into the heterocyclic 
scaffold and a methyl group into the dilactam ring led to 2-chloro-5-methyl- 
benzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)-dione (10h). These structural modifications 
resulted in the enhancement of the cytotoxicity of 10h which exhibited cytotoxic effect for all tested 
cell lines (IC50 = 170.5 µM—EUFA, ˃ 200 µM—HEK293, 107.4 µM—HeLa, 148.6 µM—U87). Finally, 
the conversion of 10c into its dithiolactam analogue: 8-bromo-2,3-dimethoxy- 
dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dithione (10p) caused the appearance of a cytotoxic effect 
on cancer cell lines (IC50 ˃ 200 µM—EUFA, ˃ 200 µM—HEK293, 115.2 µM—HeLa, 170.2 µM—U87) 
suggesting that such structural modification is beneficial for increasing the cytotoxic effect of these 
compounds. 
 
Figure 4. Flow cytometry analysis of HEK293, HeLa and U87 cells stained with 
Annexin-FITC (A) and propidium iodide (PI). Cells were treated with 200 µM compounds 
for 24 or 48 h. Camptothecin (10 µM) and H2O2 (100 µM) were used as experimental controls. 
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To measure the induction of apoptosis, cells were treated with 200 µM of 10f, 10h, 10j, 10k and 
10p compound, for 24 and 48 h (Figure 4). The experiment was performed on one normal (HEK293) 
and two cancer (HeLa, U87) cell lines. After 24 h of treatment, the HEK293 cells showed significant 
increase in necrosis and late apoptosis, as follows: 20% and 0.4% in control cells, 39% and 0.5% for 
10f, 32% and 3% for 10h, 22% and 10% for 10j. After 48 h of treatment, a slight increase in early and 
late apoptosis was observed, namely, 6.6% and 3% for 10f, 3.8% and 3.2% for 10h, 4% and 4.4% for 
10j, in comparison to 1.3% and 0.5% in control cells. 
The HeLa cells were the most sensitive to compound 10p, with a significant increase only in 
necrotic phase. After 24 h, the percentage of necrotic cells was 34.5% in comparison to 21.1% in the 
non-treated control, and 53.4% in comparison to 22.1% in control cells after 48 h treatment. The U87 
cells were sensitive to three out of five compounds tested. In the control, after 24 h, there were 1.2% 
of cells in early apoptosis, 1.6% in late apoptosis, and 8.6% in necrosis. For 10h treatment, cells were 
at 4.1% in early apoptosis and 6.9% in late apoptosis; for 10j at 5.2% in late apoptosis and 17.8% in 
necrosis; and for 10p at 14% in necrosis. After 48 h, we observed a significant increase in necrotic 
phase only, as follows: in control to 17%, for 10h to 36.2%, for 10j to 28.1%, and for 10p to 46.6%. 
Although compound 10k showed cytotoxicity to all tested human cell lines, we did not 
observe any changes in the apoptosis/necrosis phases in relation to control. It is possible that the 
compound shows not cytotoxic but cytostatic activity. 
Many different natural products possessing a lactam ring (such as β-lactam antibiotics [15]) or 
dilactam ring (diketopiperazines [16]) exhibit a strong antimicrobial effect. For this reason, we 
evaluated compounds 10a–o for their antibacterial activity. Antibacterial studies were carried out 
against two Gram-positive (Bacillus megaterium, Staphylococcus aureus RN4220) and six 
Gram-negative bacterial strains (Escherichia coli AB1157, Pseudomonas putida KT2440, Shewanella 
oneidensis MR-1, Salmonella typhimurium TA98, Salmonella typhimurium TA100, Pseudomonas 
aeruginosa PAO1). The results showed none of the synthesized compounds exhibited antibacterial 
properties at the concentrations of 12.5, 33.3, 50 and 100 µM. Even though the obtained products 
exhibited rather weak cytotoxic and no antibacterial activity in the tested range of concentrations, 
further research with the use of dibenzo[b,f][1,5]diazocine-6,12(5H,11H)diones as privileged 
structures useful in the design of bioactive compounds is underway in our laboratory and will be 
published in due course. 
3. Materials and Methods 
3.1. Chemistry 
3.1.1. General Information 
Commercially available chemicals were of reagent grade and used as received. Purification of 
the compounds was performed by column chromatography on silica gel 60 M (0.040–0.063 mm, E. 
Merck, Darmstadt, Germany). Thin layer chromatography (TLC), using silica gel plates (Kieselgel 
60F254, E. Merck), was used to monitor reaction progress. A B-540 Melting Point apparatus (Büchi, 
New Castle, DE, USA) was used to measure melting points. The 1H-NMR and 13C-NMR spectra, in 
DMSO-d6 and CDCl3, were recorded at the Department of Chemistry, University of Warsaw, using 
an AVANCE III HD 300 MHz spectrometer (Bruker, Billerica, MA, USA); shift values in parts per 
million are relative to the SiMe4 internal reference. The resonance assignments were based on peak 
multiplicity and peak integration of recorded spectra, Multiplets were assigned as bs (broad 
singlet), s (singlet), d (doublet), t (triplet) dd (doublet of doublet), ddd (doublet of doublet of 
doublet) and m (multiplet). An LTQ Orbitrap Velos instrument (Thermo Scientific, Waltham, MA, 
USA) located at the Mass Spectrometry Laboratory of the Institute of Biochemistry and Biophysics 
PAS (Warsaw, Poland) was used to record high resolution mass spectra. A 6200 FT/IR spectrometer 
(Jasco, Easton, MD, USA) at the Laboratory of Optical Spectroscopy (Institute of Organic Chemistry 
PAS, Warsaw, Poland) was used to record IR spectra. 
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3.1.2. General Procedure for the Synthesis of 2-(2-aminobenzamido)benzoic acids 15a–k. 
A suspension of 1H-benzo[d][1,3]oxazine-2,4-dione 13a–i (1 equiv.), 2-aminobenzoic acid 14a–d 
(1 equiv.) and sodium hydroxide (1 equiv.) in water (10 mL/mmol) was heated at 80 °C for 30 min 
until the evolution of carbon dioxide had ceased and a clear solution had formed. After cooling the 
reaction mixture, the obtained solution was diluted with water, and the crude product was 
precipitated by addition of glacial acetic acid, filtered and dried under vacuum. In cases of N-alkyl 
1H-benzo[d][1,3]oxazine-2,4-diones where a gummy-like residue was formed, the crude product 
was extracted with ethyl acetate, the organic phase was washed with brine and dried over 
anhydrous magnesium sulfate. Evaporation of the solvent left a glass-like residue which was used 
in next step without further purification. 
3.1.3. General Procedure for the Synthesis of 2-(2-aminobenzamido)benzoic acids methyl esters 
16a–k 
2-(2-Aminobenzamido)benzoic acids 15a–k were dissolved in methanol (ca. 10 mL/mmol) then, 
concentrated sulfuric acid was added (0.5 mL/mmol) (caution: exothermic). The resulted solution 
was refluxed for 72 h. The excess of methanol was evaporated and the resulting residue was added 
to water. The pH was adjusted to 8 by addition of NaOH and the crude products were extracted 
with ethyl acetate. The combined organic layers were washed with 1 N sodium hydroxide, water 
and brine, and then dried over anhydrous magnesium sulfate. Evaporation of solvent yielded a 
dark residue of crude methyl esters 16a–k, which were used in the next step without further 
purification. 
3.1.4. General Procedure for the Synthesis of dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-diones 10a–k 
from 2-(2-aminobenzamido)benzoic acids methyl esters 16a–k 
2-(2-Aminobenzamido)benzoic acids methyl esters 16a–k were dissolved in the anhydrous 
THF (20 mL/mmol) then 60% sodium hydride in mineral oil (2 equiv.) was added and the resulted 
solution was refluxed for 18 h. The excess of THF was evaporated, the obtained residue was poured 
into 1 N HCl and the crude product was extracted with ethyl acetate. The combined organic layers 
were washed with 1 N HCl, water and brine, then dried over anhydrous magnesium sulfate. Crude 
products were purified by column chromatography using hexane/EtOAc 1:1 then 2:8 v/v as eluent. 
2-Chlorodibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10a): Yield 33%, colourless crystals, m.p. 
275–276 °C, R.f. = 0.40 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 10.33 (s, 1H, NH), 10.25 
(s, 1H, NH), 7.45–7.21 (m, 5H, HAr), 7.11 (d, 1H, J = 2.4 Hz, HAr), 7.09 (d, 1H, J = 1.8 Hz, HAr); 
13C-NMR (DMSO-d6) δ 169.1, 167.6, 135.3, 134.4, 133.8, 133.3, 131.4, 130.7, 130.4, 128.2, 127.7, 127.6, 
127.5, 125.9; IR (KBr): cm−1 3183, 3055, 2900, 1658, 1601, 1578, 1484, 1415, 1366, 1261, 1229, 1145, 1111; 
HRMS (ESI): m/z [M+H]+ calcd for C14H10ClN2O2: 273.04253, 275.03958, found: 273.04202, 275.03904; 
2-Bromodibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10b): Yield 35%, colourless crystals, m.p. 
283–284 °C, R.f. = 0.43 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 10.33 (s, 1H, NH), 10.24 
(s, 1H, NH), 7.53 (dd, 1H, J = 2.4, 8.4 Hz, HAr), 7.49 (d, 1H, J = 2.4 Hz, HAr), 7.42–7.21 (m, 3H, HAr), 
7.10 (d, 1H, J = 7.8 Hz, HAr), 7.03 (d, 1H, J = 8.4 Hz, HAr); 13C-NMR (DMSO-d6) δ 169.0, 167.5, 135.5, 
134.4, 134.2, 133.3, 133.2, 130.7, 130.6, 128.2, 127.8, 127.5, 125.9, 119.6; IR (KBr): cm−1 3182, 3056, 2900, 
1657, 1602, 1480, 1411, 1362, 1260, 1229, 1142, 1100; HRMS (ESI): m/z [M+H]+ calcd for C14H10BrN2O2: 
316.99202, 318.98997, found: 316.99140, 318.98930; 
8-Bromo-2,3-dimethoxydibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10c): Yield 33%, colourless 
crystals, m.p. 195–196 °C, R.f. = 0.28 (ethyl acetate). 1H-NMR (DMSO-d6) δ 10.099 (s, 1H, NH), 10.057 
(s, 1H, NH), 7.54 (dd, 1H, J = 2.4, 8.4 Hz, HAr), 7.46 (d, 1H, J = 2.4 Hz, HAr), 7.01 (d, 1H, J = 8.4 Hz, 
HAr), 6.81 (s, 1H, HAr), 6.65 (s, 1H, HAr), 3.72 (s, 3H, OCH3), 3.70 (s, 3H, OCH3); 13C-NMR (DMSO-d6) 
δ 169.0, 167.6, 150.0, 147.7, 135.6, 134.6, 133.2, 130.6, 127.85, 127.77, 124.9, 119.4, 110.4, 109.1, 55.70, 
55.66; IR (KBr): cm−1 3499, 3185, 3064, 2934, 2848, 1678, 1646, 1607, 1517, 1470, 1401, 1342, 1264, 1224, 
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1176, 1108, 1078, 1027; HRMS (ESI): m/z [M+H]+ calcd for C16H14BrN2O4: 377.01315, 379.01110, found: 
377.01246, 379.01037; 
5-Methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10d): Yield 31%, colourless crystals, m.p. 
258–259 °C, R.f. = 0.36 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 10.25 (s, 1H, NH), 
7.45–7.15 (m, 7H, HAr), 7.07–6.98 (m, 1H, HAr), 3.33 (s, 1H, CH3, partially overlapped with H2O 
signal); 13C-NMR (DMSO-d6) δ 168.9, 167.4, 140.1, 134.7, 134.4, 133.3, 130.9, 130.2, 128.2, 127.9, 127.5, 
127.1, 125.7, 125.4, 36.5; IR (KBr): cm−1 3257, 3067, 2979, 2934, 1991, 1938, 1836, 1673, 1623, 1599, 1575, 
1470, 1415, 1386, 1351, 1302, 1260, 1226, 1185, 1161, 1141, 1082, 1034; HRMS (ESI): m/z [M+H]+ calcd 
for C15H13N2O2: 253.09715, found: 253.09682; 
2-Bromo-11-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10e): Yield 30%, colourless crystals, 
m.p. 247–248 °C, R.f. = 0.46 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 10.30 (s, 1H, NH), 
7.53–7.25 (m, 6H, HAr), 7.00 (d, 1H, J = 8.4 Hz, HAr), 3.32 (s, 1H, CH3, partially overlapped with H2O 
signal); 13C-NMR (DMSO-d6) δ 186.7, 165.8, 139.7, 136.3, 134.2, 133.1, 132.9, 131.2, 130.3, 128.5, 127.6. 
127.5, 125.8, 119.4, 36.5; IR (KBr): cm−1 3172, 3087, 2881, 1681, 1635, 1597, 1473, 1427, 1399, 1370, 1345, 
1300, 1274, 1240, 1180, 1135, 1079, 1038, 1014; HRMS (ESI): m/z [M+H]+ calcd for C15H12BrN2O2: 
331.00767, 333.00562, found: 331.00718, 333.00503; 
11-Methyl-2-nitrodibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10f): Yield 25%, colourless crystals, 
m.p. 225–226 °C, R.f. = 0.46 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 10.74 (s, 1H, NH), 
8.18-8.09 (m, 2H, HAr), 7.50–7.41 (m, 2H, HAr), 7.36–7.26 (m, 3H, HAr), 3.37 (s, 1H, CH3, overlapped 
with H2O signal); 13C-NMR (DMSO-d6) δ 168.6, 165.3, 145.5, 140.5, 139.6, 134.9, 132.4, 131.4, 128.7, 
127.8, 126.4, 125.9, 125.3, 123.6, 36.6; IR (KBr): cm−1 3177, 3056, 2907, 1946, 1712, 1676, 1628, 1528, 
1485, 1335, 1260, 1239, 1178, 1137, 1089; HRMS (ESI): m/z [M+H]+ calcd for C15H12N3O4: 298.08223, 
found: 298.08160; 
2,3-Dimethoxy-11-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10g): Yield 29%, colourless 
crystals, m.p. 271–272 °C, R.f. = 0.23 (ethyl acetate). 1H-NMR (, DMSO-d6) δ 9.97 (s, 1H, NH), 
7.46–7.37 (m, 2H, HAr), 7.37–7.27 (m, 3H, HAr), 6.77 (s, 1H, HAr), 6.59 (s, 1H, HAr), 3.68 (s, 3H, OCH3), 
3.67 (s, 3H, OCH3), 3.30 (s, 1H, CH3); 13C-NMR (DMSO-d6) δ 168.9, 167.3, 149.6, 147.4, 140.5, 133.3, 
130.9, 128.1, 129.0, 127.6, 126.1, 125.6, 110.2, 108.7, 55.65, 55.62, 36.6; IR (KBr): cm−1 3193, 3000, 2936, 
2841, 1674, 1626, 1513, 1478, 1454, 1431, 1398, 1364, 1302, 1258, 1223, 1156, 1133, 1105, 1082, 1036, 
1021; HRMS (ESI): m/z [M+H]+ calcd for C17H17N2O4: 313.11828, found: 313.11760; 
2-Chloro-5-methylbenzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)-dione (10h): Yield 34%, beige 
crystals, m.p. 270–271 °C, R.f. = 0.56 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 10.59 (s, 
1H, NH), 7.98–7.82 (m, 3H, HAr), 7.62 (s, 1H, HAr), 7.58–7.36 (m, 5H, HAr), 3.37 (s, 1H, CH3); 13C-NMR 
(DMSO-d6) δ 167.6, 167.3, 138.6, 135.6, 133.4, 133.0, 132.6, 131.8, 131.1, 131.0, 128.1, 128.0, 127.78, 
127.76, 127.5, 127.1, 126.9, 123.6, 36.5; IR (KBr): cm−1 3157, 3117, 3052, 2965, 2924, 2887, 1939, 1913, 
1839, 1768, 1670, 1630, 1594, 1475, 1420, 1351, 1302, 1274, 1228, 1164, 1129, 1106; HRMS (ESI): m/z 
[M+H]+ calcd for C19H14ClN2O2: 337.07383, 339.07088, found: 337.07313, 339.07024; 
5-Benzyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10i): Yield 29%, beige crystals, m.p. 212–213 °C, 
R.f. = 0.60 (hexane:ethyl acetate). 1H-NMR (DMSO-d6) δ 10.26 (s, 1H, NH), 7.37–7.18 (m, 12H, HAr), 
7.05–7.00 (m, 1H, HAr), 5.32 (d, 1H, J = 15.0 Hz, CH2), 4.81 (d, 1H, J = 15.0 Hz, CH2); 13C-NMR 
(DMSO-d6) δ 168.9, 167.8, 138.9, 136.7, 134.8, 134.3, 133.9, 130.8, 130.3, 128.3, 128.2, 127.9, 127.84, 
127.76, 127.3, 127.1, 125.9, 125.4, 52.4; IR (KBr): cm−1 3166, 3037, 2952, 2898, 1969, 1829, 1735, 1664, 
1638, 1598, 1486, 1454, 1402, 1379, 1301, 1240, 1153, 1104, 1076, 1042; HRMS (ESI): m/z [M+H]+ calcd 
for C21H17N2O2: 329.12845, found: 329.12792; 
5-(4-Bromobenzyl)dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10j): Yield 30%, colourless crystals, 
m.p. 222–223 °C, R.f. = 0.66 (hexane:ethyl acetate). 1H-NMR (DMSO-d6) δ 10.24 (s, 1H, NH), 
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7.51–7.15 (m, 12H, HAr), 7.06–6.98 (m, 1H, HAr), 5.35 (d, 1H, J = 15.0 Hz, CH2), 4.72 (d, 1H, J = 15.0 Hz, 
CH2); 13C- NMR (DMSO-d6) δ 168.6, 167.7, 138.6, 136.1, 134.8, 134.2, 133.9, 131.2, 130.9, 130.35, 130.32, 
128.4, 127.8, 127.7, 127.1, 126.0, 125.4, 120.5, 51.7; IR (KBr): cm−1 3219, 3059, 2939, 1901, 1672, 1633, 
1598, 1488, 1467, 1395, 1353, 1307, 1285, 1258, 1217, 1158, 1103, 1068, 1024, 1009; HRMS (ESI): m/z 
[M+H]+ calcd for C21H16BrN2O2: 407.03897, 409.03692, found: 407.03841, 409.03626; 
2-Bromo-11-methyl-5-(naphthalen-1-ylmethyl)dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10k): Yield 
18%, colourless crystals, m.p. 255–256 °C, R.f. = 0.40 (hexane:ethyl acetate 7:3 v/v). 1H-NMR 
(DMSO-d6) δ 8.18–8.06 (m, 1H, HAr), 7.98–7.88 (m, 1H, HAr), 7.82 (d, 1H, J = 8.1 Hz, HAr), 7.60–7.22 (m, 
9H, HAr), 7.16–7.07 (m, 2H, HAr), 6.16 (d, 1H, J = 15.0 Hz, CH2), 4.98 (d, 1H, J = 15.0 Hz, CH2), 3.05 (s, 
1H, CH3); 13C-NMR (DMSO-d6) δ 166.8, 164.5, 139.8, 137.3, 136.6, 133.7, 133.4, 133.3, 131.4, 131.3, 
131.0, 130.0, 128.6, 128.5, 128.4, 128.3, 127.6, 127.4, 126.3, 125.8, 125.7, 125.0, 123.3, 120.5, 48.8, 35.8; IR 
(KBr): cm−1 3039, 3037, 3006, 2978, 2930, 2904, 2875, 1731, 1663, 1641, 1597, 1510, 1469, 1452, 1422, 
1409, 1355, 1285, 1259, 1209, 1175, 1155, 1123, 1082, 1042, 1016; HRMS (ESI): m/z [M+H]+ calcd for 
C26H20BrN2O2: 471.07027, 473.06819, found: 471.07027, 473.06822; 
3.1.5. General Procedure for the Synthesis of 8-chloropyrido[3,2-c][1,5] benzodiazocine-5,11- 
(6H,12H)-dione (10l) and 8-chloropyrazino[3,2-c][1,5]benzodiazocine- 6,12(5H,11H)-dione (10m) 
Synthesis of 2-amino-N-sulfinylnicotinoyl chloride (19a) and 3-amino-N-sulfinyl- 
pyrazine-2-carbonyl chloride (19b). 
2-Aminonicotinic acid (18a) or 3-amino-2-pyrazinecarboxylic acid (18b) was suspended in dry 
toluene (10 mL/mmol), then thionyl chloride (5 equiv.) was added dropwise. The obtained slurry 
was refluxed for 3 h, until clear solution was formed. The excess of solvent was evaporated, and the 
residue was co-evaporated with toluene to remove traces of thionyl chloride. Crude products 19a,b 
were used in the next step without further purification. 
Synthesis of methyl 2-(2-aminonicotinamido)-5-chlorobenzoate (21a) and methyl 
2-(2-aminopyrazine-3-carboxamido)-5-chlorobenzoate (21b). 
2-Amino-N-sulfinylnicotinoyl chloride (19a) or 3-amino-N-sulfinylpyrazine-2-carbonyl 
chloride (19b) (1 equiv.) was dissolved in dry toluene (10 mL/mmol), then the solution of methyl 
2-amino-5-chlorobenzoate (20) (1 equiv.) in toluene (10 mL/mmol) was added dropwise. The 
mixture was stirred at ambient temperature for 48 h, then the solvent was evaporated and the 
obtained residue was dissolved in ethyl acetate. The organic phase was washed two times with 1 N 
NaOH, water and brine, then dried over anhydrous magnesium sulfate. Evaporation of the solvent 
resulted in crude methyl esters 21a-b which were used in next step without further purification. 
Cyclisation of methyl 2-(2-aminonicotinamido)-5-chlorobenzoate (21a) and methyl 
2-(2-aminopyrazine-3-carboxamido)-5-chlorobenzoate (21b). 
Methyl 2-(2-aminonicotinamido)-5-chlorobenzoate (21a, 1 equiv.) and methyl 
2-(2-aminopyrazine-3-carboxamido)-5-chlorobenzoate (21b, 1 equiv.) were dissolved in anhydrous 
THF (20 mL/mmol) then 60% sodium hydride in mineral oil (2 equiv.) was added. The resulting 
solution was refluxed for 18 h. The excess of THF was evaporated, residue was poured into 1 N HCl 
and the crude product was extracted with ethyl acetate. The combined organic layers were washed 
with 1 N HCl, water and brine, then dried with anhydrous magnesium sulfate. Crude products 
10l,m were purified by column chromatography using hexane/EtOAc 1:1 then 2:8 v/v as eluent. 
8-Chloropyrido[3,2-c][1,5]benzodiazocine-5,11(6H,12H)-dione (10l): Yield 17%, colourless crystals, m.p. 
308-309 °C, R.f. = 0.26 (hexane:ethyl acetate). 1H-NMR (DMSO-d6) δ 10.84 (s, 1H, NH), 10.46 (s, 1H, 
NH), 8.46 (dd, 1H, J = 1.8, 4.8 Hz, HAr), 7.84 (dd, 1H, J = 1.8, 7.5 Hz, HAr), 7.49–7.40 (m, 2H, HAr), 7.48 
(dd, 1H, J = 4.8, 7.8 Hz, HAr), 7.18–7.11 (m, 1H, HAr); 13C-NMR (DMSO-d6) δ 167.7, 167.3, 150.6, 147.0, 
138.1, 134.6, 133.6, 131.7, 130.8, 128.0, 127.90, 127.64, 123.1; IR (KBr): cm−1 3182, 3066, 2937, 2902, 
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1924, 1675, 1596, 1486, 1459, 1433, 1410, 1328, 1281, 1254, 1226, 1150, 1110; HRMS (ESI): m/z [M+H]+ 
calcd for C13H9ClN3O2: 274.03778, 276.03483, found: 274.0372, 276.03436; 
8-Chloropyrazino[3,2-c][1,5]benzodiazocine-6,12(5H,11H)-dione (10m): Yield 19%, colourless crystals, 
m.p. 346–347 °C, R.f. = 0.35 (hexane:ethyl acetate). 1H-NMR (DMSO-d6) δ 11.24 (s, 1H, NH), 10.77 (s, 
1H, NH), 8.65–8.50 (m, 2H, HAr), 7.55–7.40 (m, 2H, HAr), 7.30–7.18 (m, 2H, HAr); 13C-NMR (DMSO-d6) 
δ 167.1, 165.5, 144.9, 144.5, 144.1, 143.7, 134.1, 132.8, 132.2, 131.1, 128.2, 127.8; IR (KBr): cm−1 3249, 
3164, 3057, 2961, 2891, 1928, 1685, 1571, 1537, 1484, 1458, 1406, 1343, 1276, 1236, 1211, 1150, 1133, 
1108, 1064; HRMS (ESI): m/z [M+H]+ calcd for C12H8ClN4O2: 275.03303, 277.03008, found: 275.03247, 
277.02957; 
3.1.6. Synthesis of ethyl 2-(11-methyl-6,12-dioxo-11,12-dihydrodibenzo[b,f][1,5]diazocin- 
5(6H)-yl)acetate (10n) 
5-Methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10d, 252 mg, 1 mmol, 1 equiv.) was 
dissolved in anhydrous DMSO (5 mL), then 60% NaH dispersed in mineral oil (48 mg, 1.2 mmol, 1.2 
equiv.) was added. The resulted suspension was stirred at room temperature for 30 min. until 
evolution of gas ceased. Then, ethyl bromoacetate (133 µL, 1.2 mmol, 1.2 equiv.) was added 
dropwise, and the resulting solution was stirred for 18 h at room temperature. The next day, the 
reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (3 × 20 mL). 
Combined organic layers were washed with brine (1 × 20 mL) and dried over anhydrous 
magnesium sulfate, followed by evaporation under reduced pressure. Crude product was purified 
by column chromatography using hexane/EtOAc 1:1 then 2:8 v/v as eluent. Yield 78% (264 mg), 
colourless crystals, m.p. 125–126 °C, R.f. = 0.66 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 
7.45-7.15 (m, 8H, HAr), 4.62 (d, 1H, J = 17.1 Hz, CH2), 4.47 (d, 1H, J = 17.1 Hz, CH2), 4.23–4.10 (m, 2H, 
CH2), 1.22 (t, 3H, J = 7.2 Hz, CH3); 13C-NMR (DMSO-d6) δ 168.3, 167.6, 166.9, 140.1, 139.0, 134.3, 133.2, 
131.0, 130.8, 128.2, 128.1, 127.6, 127.2, 125.6, 125.2, 60.9, 51.1, 36.1, 14.0; IR (KBr): cm−1 3458, 3300, 
3058, 2981, 2936, 1953, 1840, 1739, 1656, 1599, 1456, 1411, 1411, 1375, 1324, 1308, 1281, 1260, 1217, 
1120, 1088, 1056, 1023; HRMS (ESI): m/z [M+H]+ calcd for C19H19N2O4: 339.13393, found: 339.13393; 
3.1.7. Synthesis of 5-acetyl-11-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10o) 
The dispersion of 5-methyldibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10d) (504 mg, 2 
mmol, 1 equiv.) in acetic anhydride (10 mL) was refluxed for 3 h. The excess anhydride was 
evaporated under reduced pressure and the residue was crystallized from a mixture of cyclohexane 
and ethyl acetate (9:1) to give pure product. Yield 89% (524 mg), colourless crystals, m.p. 193–194 
°C, R.f. = 0.74 (hexane:ethyl acetate 2:8 v/v). 1H-NMR (DMSO-d6) δ 7.46-7.19 (m, 8H, HAr), 3.34 (s, 1H, 
CH3), 2.61 (s, 1H, CH3); 13C-NMR (DMSO-d6) δ 171.5, 168.6, 166.7, 139.7, 135.4, 134.3, 133.8, 132.1, 
130.3, 129.4, 129.0, 128.3, 127.8, 127.0, 126.2, 36.0, 26.7; IR (KBr): cm−1 3412, 3379, 3296, 3061, 2938, 
1975, 1941, 1718, 1703, 1658, 1599, 1485, 1453, 1420, 1371, 1304, 1251, 1206, 1142, 1084, 1038, 1013; 
HRMS (ESI): m/z [M+H]+ calcd for C17H15N2O3: 295.10772, found: 295.10735; 
3.1.8. Synthesis of 8-bromo-2,3-dimethoxydibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dithione (10p) 
Bromo-2,3-dimethoxydibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione (10c, 376 mg, 1 mmol, 1 
equiv.) was dissolved in dry THF and then p-tolyl Davy-reagent (873 mg, 2 mmol, 2 equiv.) was 
added. The resulting suspension was refluxed for 18 h, then the reaction mixture was cooled to 
room temperature. The obtained clear, yellow solution was evaporated with small amount of 
chromatographic silica gel. The crude product was purified by column chromatography using 
hexane/EtOAc 9:1 then 7:3 v/v as eluent. Yield 58% (237 mg), yellow solid, m.p. 186–187 °C 
(decomposition), R.f. = 0.27 (hexane:ethyl acetate 7:3 v/v). 1H-NMR (DMSO-d6) δ 12.30 (s, 1H, NH), 
12.28 (s, 1H, NH), 7.56–7.49 (m, 2H, HAr), 6.99 (d, 1H, J = 5.1 Hz, HAr), 6.88 (s, 1H, HAr), 6.64 (s, 1H, 
HAr), 3.73 (s, 3H, OMe), 3.70 (s, 3H, OMe); 13C-NMR (DMSO-d6) δ 200.2, 197.5, 149.8, 148.0, 141.2, 
133.1, 132.9, 131.2, 131.1, 126.9, 126.6, 120.4, 111.4, 107.7, 55.9, 55.7; IR (KBr): cm−1 3439, 3248, 2925, 
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2644, 1602, 1506, 1403, 1345, 1265, 1227,1200, 1141, 1079, 1030; HRMS (ESI): m/z [M+H]+ calcd for 
C16H14BrN2O2S2: 408.96746, 410.96541, found: 408.96725, 410.96512; 
3.1.9. General Procedure for the Synthesis of 1-Substituted 1H-benzo[d][1,3]oxazine-2,4-diones 13f–i 
To a stirred solution of 6-chloro-1H-benzo[d][1,3]oxazine-2,4-dione (13a), 6-bromo-1H- 
benzo[d][1,3]oxazine-2,4-dione (13b) or 1H-benzo[d][1,3]oxazine-2,4-dione (13c) (1 equiv.) in DMSO 
(10 mL/mmol), 60% sodium hydride (1.5 equiv.) was added and the resulting suspension was 
stirred for 15 min. at room temperature, until the evolution of gas ceased. Then, the appropriate 
halide (1.5 equiv.): methyl iodide for 13a, 1-(bromomethyl)naphthalene for 13b or benzyl bromide 
and 4-bromobenzyl bromide for 13c, was added and the resulting mixture was stirred at room 
temperature for 18 h. Next day, the reaction mixture was poured into water (100 mL/10mL DMSO) 
and extracted with ethyl acetate (3 × 100 mL/100mL H2O). Combined organic layers were washed 
with brine (100 mL/300 mL EtOAc) and dried over anhydrous magnesium sulfate. Crude products 
were crystallized from mixture of ethyl acetate and hexane. 
6-Chloro-1-methyl-1H-benzo[d][1,3]oxazine-2,4-dione (13f): Yield 62%, yellow crystals, m.p. 201–202 °C, 
R.f. = 0.33 (hexane:ethyl acetate 7:3). 1H-NMR (DMSO-d6) δ 7.94 (d, 1H, J = 2.4 Hz, HAr), 7.89 (dd, 1H, 
J = 2.4, 9.0 Hz, HAr), 7.48 (d, 1H, J = 9.0 Hz, HAr), 3.46 (s, 1H, Me); 13C-NMR (DMSO-d6) δ 158.0, 147.4, 
141.1, 136.6, 127.9, 127.6, 117.1, 113.3, 31.9; HRMS (ESI): m/z [M+H]+ calcd for C9H7ClNO3: 212.01090, 
214.00795, found: 212.01049, 214.00754; 
1-Benzyl-1H-benzo[d][1,3]oxazine-2,4-dione (13g): Yield 57%, beige crystals, m.p. 141–142 °C, R.f. = 
0.54 (hexane:ethyl acetate 7:3). 1H-NMR (DMSO-d6) δ 8.04 (dd, 1H, J = 1.5, 7.8 Hz, HAr), 7.73 (ddd, 
1H, J = 1.5, 7.2, 8.7 Hz, HAr), 7.46–7.20 (m, 7H, HAr), 5.30 (s, 2H, CH2); 13C-NMR (DMSO-d6) δ 158.9, 
148.3, 141.3, 137.0, 135.3, 129.5, 128.6, 127.4, 126.6, 123.7, 115.1, 112.1, 47.6; HRMS (ESI): m/z [M+H]+ 
calcd for C15H12NO3: 254.08116, found: 254.08104; 
1-(4-Bromobenzyl)-1H-benzo[d][1,3]oxazine-2,4-dione (13h): Yield 62%, beige crystals, m.p. 182–183 °C, 
R.f. = 0.50 (hexane:ethyl acetate 7:3). 1H-NMR (DMSO-d6) δ 8.04 (dd, 1H, J = 1.5, 7.8 Hz, HAr), 7.74 
(ddd, 1H, J = 1.5, 7.2, 8.7 Hz, HAr), 7.85–7.49 (m, 2H, HAr), 7.44–7.36 (m, 2H, HAr), 7.35–7.26 (m, 1H, 
HAr), 7.22 (dd, 1H, J = 8.4 Hz, HAr), 5.27 (s, 2H, CH2); 13C-NMR (DMSO-d6) δ 158.8, 148.3, 141.2, 137.0, 
134.8, 131.5, 129.5, 129.0, 123.8, 120.5, 115.0, 112.2, 47.0; HRMS (ESI): m/z [M+H]+ calcd for 
C15H11BrNO3: 331.99168, 333.98964, found: 331.99138, 333.98930; 
6-Bromo-1-(naphthalen-1-ylmethyl)-1H-benzo[d][1,3]oxazine-2,4-dione (13i): Yield 51%, white solid, m.p. 
230–231 °C, R.f. = 0.74 (hexane:ethyl acetate 7:3). 1H-NMR (DMSO-d6) δ 8.26–8.16 (m, 1H, HAr), 8.15 
(d, 1H, J = 2.4 Hz, HAr), 8.04–7.97 (m, 1H, HAr), 7.92–7.78 (m, 2H, HAr), 7.72–7.56 (m, 2H, HAr), 
7.42–7.33 (m, 2H, HAr), 7.02 (d, 1H, J = 9.0 Hz, HAr), 5.73 (s, 2H, CH2); 13C-NMR (DMSO-d6) δ 157.9, 
147.8, 140.8, 139.2, 133.3, 131.0, 129.9, 129.5, 128.7, 127.7, 126.5, 126.2, 125.4, 123.0, 122.2, 117.7, 115.3, 
114.52, 114.48, 46.4; HRMS (ESI): m/z [M+H]+ calcd for C19H13BrNO3: 382.0073, 384.00529 found: 
382.0645, 384.00443; 
3.1.10. DCC-mediated Synthesis of 2-(2-aminophenyl)-4H-benzo[d][1,3]oxazin-4-one (12, R1 = R2 = 
H). 
A suspension of 1H-benzo[d][1,3]oxazine-2,4-dione (13c, 489 mg, 3 mmol, 1 equiv.), 
2-aminobenzoic acid (14a, 411 mg, 3 mmol, 1 equiv.), sodium hydroxide (120 mg, 3 mmol, 1 equiv.) 
in water (30 mL) was heated at 80 °C for 30 min. until the evolution of carbon dioxide ceased and 
clear solution was formed. After cooling, the obtained solution was diluted with water, crude 
product was precipitated by addition of glacial acetic acid and the resulting precipitate was dried 
under reduced pressure. The crude 2-(2-aminobenzamido)benzoic acid (11) was dissolved in 50 mL 
of DMF, then N,N’-dicyclohexylcarbodiimide (DCC) (681 mg, 3.3 mmol, 1.1 equiv.) was added and 
the reaction mixture was stirred at room temperature for 18 h. The next day, the obtained solution 
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was poured into water (100 mL) and the product was extracted with ethyl acetate (3 × 100 mL). 
Combined organic layers were washed with brine (1 x 50 mL), dried over anhydrous magnesium 
sulfate followed by evaporation of volatiles under reduced pressure. Crude product was purified 
by column chromatography using hexane: ethyl acetate 9:1 v/v as eluent. yield 84% (600 mg), yellow 
solid, m.p. 171–172 °C, R.f. = 0.69 (hexane:ethyl acetate 7:3). 1H-NMR (CDCl3) δ 8.19 (d, 1H, J = 4.8 
Hz, HAr), 8.08 (d, 1H, J = 4.8 Hz, HAr), 7.76 (t, 1H, J = 4.7 Hz, HAr), 7.56 (d, 1H, J = 5.1 Hz, HAr), 7.44 (t, 
1H, J = 4.5 Hz, HAr), 7.26 (t, 1H, J = 4.7 Hz, HAr), 6.78–6.68 (m, 2H, HAr), 6.47 (bs, 2H, NH2); 13C-NMR 
(CDCl3) δ 159.4, 158.0, 149.8, 146.7, 136.5, 133.7, 129.7, 128.7, 127.8, 126.4, 116.9, 116.8, 116.6, 110.1; IR 
(KBr): cm−1 3448, 3311, 1743, 1625, 1592, 1550, 1489, 1471, 1447, 1356, 1331, 1310, 1235, 1220, 1167, 
1054, 1013; HRMS (ESI): m/z [M+H]+ calcd for C14H11N2O2: 239.08150, found: 239.08128; 
3.1.11. The Synthesis of methyl 2-amino-5-chlorobenzoate (20) 
To stirred slurry of 6-chloro-1H-benzo[d][1,3]oxazine-2,4-dione (13a, 591 mg, 3 mmol, 1 equiv.) 
in methanol (30 mL), sodium methoxide (486 mg, 9 mmol, 3 equiv.) was added, and the reaction 
mixture was refluxed for 3 h. After cooling down, the excess of solvent was evaporated under 
reduced pressure; the obtained residue was treated with water (100 mL) and extracted with ethyl 
acetate (3 × 50 mL). Combined organic layers were washed with water (1 × 100 mL), brine (1 × 50 
mL) and dried over anhydrous magnesium sulfate. Evaporation of solvent gave pure product as 
slight yellow oil which solidified upon storage. Yield 97% (538 mg), m.p. 70–71 °C, R.f. = 0.80 
(hexane:ethyl acetate 7:3). 1H-NMR (CDCl3) δ 7.81 (d, 1H, J = 2.4 Hz, HAr), 7.19 (dd, 1H, J = 2.4, 9.0 
Hz, HAr), 6.59 (d, 1H, J = 9.0 Hz, HAr), 5.73 (bs, 2H, NH2), 3.86 (s, 3H, Me); 13C-NMR (CDCl3) δ 167.7, 
149.1, 134.2, 130.5, 120.7, 118.1, 111.6, 51.9; HRMS (ESI): m/z [M+H]+ calcd for C8H9ClNO2: 186.03163, 
188.02868 found: 186.03171, 188.02870. 
3.2. X-ray Data Collection and Data Refinement 
Good quality single-crystals of 10b, 10g, 10h, 10i, 10j, 10l, 10m, 10o 11*TsOH, 13i and 14c, were 
selected for the X-ray diffraction experiments at T = 100(2) K. Diffraction data were collected on a 
SuperNova Dual Source diffractometer (Agilent Technologies, Yarnton, Oxfordshire, UK) with 
CuKα radiation (λ = 1.54184 Å) (10g, 10h, 10i, 10j, 10l, 10m, 10o 11*TsOH, 13i and 14c) or an Agilent 
Technologies SuperNova Single Source diffractometer with MoKα radiation (λ = 0.71073 Å) (10b), 
using CrysAlis RED software [17]. The analytical numeric absorption correction using a 
multifaceted crystal model based on expressions derived by Clark and Reid [18] (10b, 10l, 10j 10h, 
11*TsOH and 13i) and multi-scan empirical absorption correction using spherical harmonics (10i, 
10g, 10m, 10o and 14c), implemented in SCALE3 ABSPACK scaling algorithm, were applied [17]. 
The structural determination procedure was carried out using the SHELX package [19]. The 
structures were solved with direct methods and then successive least-square refinement was carried 
out based on the full-matrix least-squares method on F2 using the SHELXL programme [19]. All 
H-atoms linked to the N and O-atoms were located on a Fourier difference map and refined as 
riding with Uiso(H) = xUeq(N,O), where x = 1.2 for the amine and 1.5 for the hydroxyl H-atoms, 
respectively. In all the cases, the N−H bonds were subject to the DFIX 0.87 restraint. In the case of 
14c, length of the O−H bond was restrained to 0.82 Å. Other H-atoms were positioned 
geometrically, with C–H equal to 0.93, 0.97 and 0.98 Å for the aromatic, methylene and methine 
H-atoms, respectively, and constrained to ride on their parent atoms with Uiso(H) = xUeq(C), where x 
= 1.2 for the aromatic, methylene and methine H-atoms. In the case of 10i, a few distinct peaks on 
the difference Fourier map indicated the presence of a disordered solvent molecule. However, all of 
the attempts to model disordered solvents used for crystallization failed. Therefore, the solvent 
contribution was removed by applying the appropriate MASK procedure in the Olex2 programme 
[20]. Calculated total solvent accessible volume was 982.1 Å3 occupied by 286.6 electrons per unit 
cell. The figures for this publication were prepared using Olex2 programme [20]. 
3.3. Cell Culturing 
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Following cell lines: HeLa, U87, HEK293, EUFA30 were cultured in DMEM medium (Life 
Technology, Carlsbad, CA, United States) with 10% fetal bovine serum (Thermo Fisher Scientific, 
Waltham, MA, USA) and 0.1% antibiotics (penicillin, streptomycin, Life Technology, Carlsbad, CA, 
United States). Cells were grown in atmosphere of 5 and 95% CO2 and air, respectively, at 37 °C. 
3.4. Cytotoxicity Assay 
Exponentially growing cells at the density of 2 × 103 cells/well were seeded onto a 96-well 
plate, cultured for 18 h, and treated with newly synthesized compounds at concentrations 1–200 
µM, or with DMSO as a control, for 24 or 48 h. Alamar Blue (Thermo Fisher Scientific, Waltham, 
MA, USA) was added accordingly to manufacturer protocol. After 4 h, light emission at 590 nm was 
measured with excitation at 560 nm using a scanning multiwell spectrophotometer (DTX 880, 
Beckman Coulter, Brea, CA, United States). The experiments were repeated at least three times with 
three replicates for each inhibitor concentration. After background subtraction, inhibition rates, IC50, 
were calculated as the component concentration inhibiting cell growth by 50%. All the calculations 
were performed using Origin 9.0 software. 
3.5. Flow Cytometry 
The apoptosis detection kit (Annexin V-FITC BD Biosciences, Franklin Lakes, NJ, United 
States) was used to detect apoptosis by flow cytometry. Cells were seeded in 6-well plates at 
concentration of 5 × 105 cells/well, cultured for 18 h, and tested compound was applied for 
indicated time. Afterwards, cells were washed with PBS, resuspended in binding buffer at 
concentration of 2 × 106 cells/mL. The anti-Annexin V FITC-conjugated antibody and propidium 
iodide were added to 100 µl aliquots. Then, mixtures were incubated for 15 min at room 
temperature, supplemented with binding buffer to 500 µl and processed by BD FACSCalibur (BD 
Biosciences, Franklin Lakes, NJ, United States). Data were analyzed in Flowing Software version 
2.5.1 (Flowing Software, http://www.uskonaskel.fi/flowingsoftware). 
3.6. Disk Diffusion Test 
Bacterial inoculum was spread on LB plates solidified with 1.5% agar. Standard 6 mm paper 
discs were placed on the surface of the plates and 4 µL of tested compound at the desired 
concentration plotted on the discs. 
4. Conclusion 
In this article we have presented that asymmetrically substituted dibenzo[b,f][1,5]- 
diazocine-6,12(5H,11H)diones, which may be treated as convenient privileged structures useful in 
the design of biologically active compounds, can be obtained according to two, general methods 
based on reactions of: a) 1H-benzo[d][1,3]oxazine-2,4-diones and unprotected 2-aminobenzoic acids, 
and b) unprotected 2-aminobenzoic acid analogues, activated with thionyl chloride, and 
2-aminobenzoic acid esters. The procedures described allow a wide range of modifications of all 
structural elements of the dibenzo[b,f][1,5]diazocine-6,12(5H,11H)dione framework: the 
introduction of various substituents and functional groups into benzene rings as well as diverse 
substituents and side chains attached to the eight-membered diazocine ring. We have shown that 
these modifications can be introduced both, through the selection of appropriately modified 
building blocks as well as further chemical modifications of the obtained 
dibenzo[b,f][1,5]diazocine-6,12(5H,11H)dione scaffold. The wide range of synthetic methods has 
also allowed to obtain three new heterocyclic frameworks: 
benzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)-dione 10h, pyrido[3,2-c][1,5]benzo- 
diazocine-5,11(6H,12H)-dione 10l, and pyrazino[3,2-c][1,5]benzodiazocine-6,12(5H,11H)-dione 10m. 
The usefulness of the synthetic methods has been confirmed by obtaining a representative library of 
16 compounds, evaluated as possible cytotoxic and antimicrobial agents. 
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